ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Clomid for PCT, fertility or low T
New frontiers in fertility preservation: a hypothesis on fertility optimization in men with hypergonadotrophic hypogonadism
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 175747" data-attributes="member: 13851"><p><strong>Abstract:</strong> Strategies exist that can mitigate the risk of causing iatrogenic infertility when men require testosterone replacement therapy (TRT). This article reviews the current medical therapies that preserve spermatogenesis when TRT is indicated. Furthermore, we highlight the re-emerging concept of hypothalamic-pituitary-gonadal (HPG) axis reset in hypergonadotrophic, hypogonadal infertile men who are planning sperm retrieval procedures. Finally, we present our hypothesis for a novel protocol to optimize hypergonadotrophic hypogonadal men before sperm extraction surgeries hormonally.</p><p></p><p></p><p></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>Physiology of the HPG axis </strong></span></p><p></p><p>Male fertility and proper functioning of the HPG axis are closely intertwined. Spermatogenesis depends on the pulsatile release of gonadotropins, follicle stimulating hormone (FSH), and luteinizing hormone (LH), from the pituitary, and their action on their cells in the testis. FSH signals to FSH receptors (FSHR) on Sertoli cells to initiate spermatogenesis, whereas LH signals to LH receptors (LHR) on Leydig cells to produce intratesticular testosterone (<a href="http://tau.amegroups.com/article/view/36614/28657#B2" target="_blank">2</a>). The qualitative and quantitative integrity of these receptors plays an equally significant role in the regulation of spermatogenesis. Unsurprisingly, inactivating mutations of the FSHR and LHR results in impaired fertility (<a href="http://tau.amegroups.com/article/view/36614/28657#B3" target="_blank">3</a>,<a href="http://tau.amegroups.com/article/view/36614/28657#B4" target="_blank">4</a>). However, gonadotrophic overstimulation can also have a detrimental effect on spermatogenesis by downregulating the expression of LHR and FSHR (<a href="http://tau.amegroups.com/article/view/36614/28657#B5" target="_blank">5</a>). This effect may explain the clinical observations of Ross <em>et al.</em>, who observed a reversible decline in sperm motility following high dose administration of selective estrogen receptor modulators (SERMs), which function by increasing the gonadotropin levels (<a href="http://tau.amegroups.com/article/view/36614/28657#B6" target="_blank">6</a>).</p><p></p><p>High intratesticular testosterone (ITT) levels maintain the spermatogenic process and prevent germ cell death (<a href="http://tau.amegroups.com/article/view/36614/28657#B7" target="_blank">7</a>). Low ITT levels result in an impaired blood-testis barrier permitting immune cells to enter the seminiferous tubules and attack autoantigenic germ cells [reviewed by Walker (<a href="http://tau.amegroups.com/article/view/36614/28657#B8" target="_blank">8</a>)]. Low intratesticular testosterone levels also block the conversion of round spermatids to elongating spermatogonia and prevent spermiation, leading to phagocytosis of spermatids by Sertoli cells (<a href="http://tau.amegroups.com/article/view/36614/28657#B8" target="_blank">8</a>,<a href="http://tau.amegroups.com/article/view/36614/28657#B9" target="_blank">9</a>).</p><p></p><p>It is well established that exogenous testosterone therapy causes azoospermia in the majority of men (<a href="http://tau.amegroups.com/article/view/36614/28657#B10" target="_blank">10</a>). Exogenous testosterone’s contraceptive effect occurs through its suppression of the HPG axis, preventing LH and FSH release and their respective gonadal functions (<a href="http://tau.amegroups.com/article/view/36614/28657#B11" target="_blank">11</a>). Studies examining the reproductive outcomes and rates of azoospermia development of various testosterone treatment modalities show less detrimental effects with testosterone patches [24% rate of azoospermia (<a href="http://tau.amegroups.com/article/view/36614/28657#B12" target="_blank">12</a>)] compared to intramuscular injections of testosterone enanthate, which result in up to an 98% rate of combined azoospermia and oligozoospermia (≤3 million/cc) after 1 year of therapy (<a href="http://tau.amegroups.com/article/view/36614/28657#B13" target="_blank">13</a>).</p><p></p><p>In a male contraceptive study, Coviello <em>et al.</em> followed seven healthy men with serum hormone assessments and percutaneous testicular aspirates to assess intratesticular hormone levels (<a href="http://tau.amegroups.com/article/view/36614/28657#B14" target="_blank">14</a>). They showed a 98% suppression of LH, 97% suppression of FSH, and 93% suppression of intratesticular androgenic bioactivity levels following weekly administrations of intramuscular testosterone enanthate (TE) 100 mg with levonorgestrel over a 6-month treatment period compared to baseline. Levonorgestrel was administered to suppress the HPG axis further. One subject failed to suppress spermatogenesis with a nadir sperm count of 3.4 mill/mL despite a reduction in his ITT level from 1,607 to 29 nmol/L (98% reduction). This study demonstrates the heterogeneity in TRT’s contraceptive effect and the variability in intratesticular testosterone levels necessary for spermatogenesis to occur. Conversely, recovery of the HPG axis function following testosterone therapy cessation is possible but can take between 110 days and 2 years (<a href="http://tau.amegroups.com/article/view/36614/28657#B15" target="_blank">15</a>,<a href="http://tau.amegroups.com/article/view/36614/28657#B16" target="_blank">16</a>).</p><p></p><p></p><p></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">*</span>Strategies to preserve fertility when testosterone therapy cannot be stopped </strong></p><p></p><p><span style="color: rgb(184, 49, 47)">-HCG </span></p><p><span style="color: rgb(184, 49, 47)">-Selective estrogen receptor modulators and aromatase inhibitors </span></p><p><span style="color: rgb(184, 49, 47)">-Nasal testosterone</span></p><p></p><p></p><p></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">*</span>HPG axis reset—a new tool in our armamentarium? </strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)">*</span>Additional evidence for HPG axis reset: an independent case series </strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Conclusions </strong></p><p></p><p>Keeping men on TRT fertile has proven to be difficult for male fertility specialists. <span style="color: rgb(184, 49, 47)">When the option of avoiding testosterone with alternative therapies, such as clomiphene citrate, aromatase inhibitors, and human chorionic gonadotropin, is not possible, some strategies can mitigate the negative impact of TRT on spermatogenesis. </span>It is important to note that these therapies are not well established, possess limitations in their applicability, and carry side effects.</p><p></p><p><span style="color: rgb(184, 49, 47)">Novel methods of treating hypogonadal symptoms and keeping men fertile include the use of </span><span style="color: rgb(44, 130, 201)">nasal testosterone </span><span style="color: rgb(184, 49, 47)">and </span><span style="color: rgb(44, 130, 201)">resetting the HPG axis with TRT and controlled administration of HCG.</span> While preliminary results suggest that these methods may increase success for fertility treatments, more extensive research is needed to demonstrate the efficacy and safety of these therapies. The most recent evidence provides hope for the future of male fertility in patients that require TRT.</p></blockquote><p></p>
[QUOTE="madman, post: 175747, member: 13851"] [B]Abstract:[/B] Strategies exist that can mitigate the risk of causing iatrogenic infertility when men require testosterone replacement therapy (TRT). This article reviews the current medical therapies that preserve spermatogenesis when TRT is indicated. Furthermore, we highlight the re-emerging concept of hypothalamic-pituitary-gonadal (HPG) axis reset in hypergonadotrophic, hypogonadal infertile men who are planning sperm retrieval procedures. Finally, we present our hypothesis for a novel protocol to optimize hypergonadotrophic hypogonadal men before sperm extraction surgeries hormonally. [COLOR=rgb(0, 0, 0)][B]Physiology of the HPG axis [/B][/COLOR] Male fertility and proper functioning of the HPG axis are closely intertwined. Spermatogenesis depends on the pulsatile release of gonadotropins, follicle stimulating hormone (FSH), and luteinizing hormone (LH), from the pituitary, and their action on their cells in the testis. FSH signals to FSH receptors (FSHR) on Sertoli cells to initiate spermatogenesis, whereas LH signals to LH receptors (LHR) on Leydig cells to produce intratesticular testosterone ([URL='http://tau.amegroups.com/article/view/36614/28657#B2']2[/URL]). The qualitative and quantitative integrity of these receptors plays an equally significant role in the regulation of spermatogenesis. Unsurprisingly, inactivating mutations of the FSHR and LHR results in impaired fertility ([URL='http://tau.amegroups.com/article/view/36614/28657#B3']3[/URL],[URL='http://tau.amegroups.com/article/view/36614/28657#B4']4[/URL]). However, gonadotrophic overstimulation can also have a detrimental effect on spermatogenesis by downregulating the expression of LHR and FSHR ([URL='http://tau.amegroups.com/article/view/36614/28657#B5']5[/URL]). This effect may explain the clinical observations of Ross [I]et al.[/I], who observed a reversible decline in sperm motility following high dose administration of selective estrogen receptor modulators (SERMs), which function by increasing the gonadotropin levels ([URL='http://tau.amegroups.com/article/view/36614/28657#B6']6[/URL]). High intratesticular testosterone (ITT) levels maintain the spermatogenic process and prevent germ cell death ([URL='http://tau.amegroups.com/article/view/36614/28657#B7']7[/URL]). Low ITT levels result in an impaired blood-testis barrier permitting immune cells to enter the seminiferous tubules and attack autoantigenic germ cells [reviewed by Walker ([URL='http://tau.amegroups.com/article/view/36614/28657#B8']8[/URL])]. Low intratesticular testosterone levels also block the conversion of round spermatids to elongating spermatogonia and prevent spermiation, leading to phagocytosis of spermatids by Sertoli cells ([URL='http://tau.amegroups.com/article/view/36614/28657#B8']8[/URL],[URL='http://tau.amegroups.com/article/view/36614/28657#B9']9[/URL]). It is well established that exogenous testosterone therapy causes azoospermia in the majority of men ([URL='http://tau.amegroups.com/article/view/36614/28657#B10']10[/URL]). Exogenous testosterone’s contraceptive effect occurs through its suppression of the HPG axis, preventing LH and FSH release and their respective gonadal functions ([URL='http://tau.amegroups.com/article/view/36614/28657#B11']11[/URL]). Studies examining the reproductive outcomes and rates of azoospermia development of various testosterone treatment modalities show less detrimental effects with testosterone patches [24% rate of azoospermia ([URL='http://tau.amegroups.com/article/view/36614/28657#B12']12[/URL])] compared to intramuscular injections of testosterone enanthate, which result in up to an 98% rate of combined azoospermia and oligozoospermia (≤3 million/cc) after 1 year of therapy ([URL='http://tau.amegroups.com/article/view/36614/28657#B13']13[/URL]). In a male contraceptive study, Coviello [I]et al.[/I] followed seven healthy men with serum hormone assessments and percutaneous testicular aspirates to assess intratesticular hormone levels ([URL='http://tau.amegroups.com/article/view/36614/28657#B14']14[/URL]). They showed a 98% suppression of LH, 97% suppression of FSH, and 93% suppression of intratesticular androgenic bioactivity levels following weekly administrations of intramuscular testosterone enanthate (TE) 100 mg with levonorgestrel over a 6-month treatment period compared to baseline. Levonorgestrel was administered to suppress the HPG axis further. One subject failed to suppress spermatogenesis with a nadir sperm count of 3.4 mill/mL despite a reduction in his ITT level from 1,607 to 29 nmol/L (98% reduction). This study demonstrates the heterogeneity in TRT’s contraceptive effect and the variability in intratesticular testosterone levels necessary for spermatogenesis to occur. Conversely, recovery of the HPG axis function following testosterone therapy cessation is possible but can take between 110 days and 2 years ([URL='http://tau.amegroups.com/article/view/36614/28657#B15']15[/URL],[URL='http://tau.amegroups.com/article/view/36614/28657#B16']16[/URL]). [B][COLOR=rgb(184, 49, 47)]*[/COLOR]Strategies to preserve fertility when testosterone therapy cannot be stopped [/B] [COLOR=rgb(184, 49, 47)]-HCG -Selective estrogen receptor modulators and aromatase inhibitors -Nasal testosterone[/COLOR] [B][COLOR=rgb(184, 49, 47)]*[/COLOR]HPG axis reset—a new tool in our armamentarium? [COLOR=rgb(184, 49, 47)]*[/COLOR]Additional evidence for HPG axis reset: an independent case series Conclusions [/B] Keeping men on TRT fertile has proven to be difficult for male fertility specialists. [COLOR=rgb(184, 49, 47)]When the option of avoiding testosterone with alternative therapies, such as clomiphene citrate, aromatase inhibitors, and human chorionic gonadotropin, is not possible, some strategies can mitigate the negative impact of TRT on spermatogenesis. [/COLOR]It is important to note that these therapies are not well established, possess limitations in their applicability, and carry side effects. [COLOR=rgb(184, 49, 47)]Novel methods of treating hypogonadal symptoms and keeping men fertile include the use of [/COLOR][COLOR=rgb(44, 130, 201)]nasal testosterone [/COLOR][COLOR=rgb(184, 49, 47)]and [/COLOR][COLOR=rgb(44, 130, 201)]resetting the HPG axis with TRT and controlled administration of HCG.[/COLOR] While preliminary results suggest that these methods may increase success for fertility treatments, more extensive research is needed to demonstrate the efficacy and safety of these therapies. The most recent evidence provides hope for the future of male fertility in patients that require TRT. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Clomid for PCT, fertility or low T
New frontiers in fertility preservation: a hypothesis on fertility optimization in men with hypergonadotrophic hypogonadism
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top